Any time you’re traveling from the west coast to the east coast, you know you’ll be in for a long flight. But any potential airport hassles are well worth the opportunity to attend ISPOR. This year in Boston, we connected with many of our colleagues and clients, and learned about new methods, emerging best practices, technological developments, and implications of policy shifts.
We also had three posters that we published, so we were eager to present our work and discuss its implications with our colleagues. This was an important aspect of this conference, as we were able to demonstrate our approach and insight on a number of topics.
As you know, ISPOR is the leading global scientific and educational organization for HEOR and its use in decision making to improve health. Accordingly, we saw a number of valuable presentations that gave us new insight about the entire life science technology industry.
In fact, there were many educational opportunities, ranging from introductory short-courses to highly specific technical presentations led by key opinion leaders.
Among the things we learned:
- Future directions for cost effectiveness analysis
- New actuarial and health economics approaches to assess value
- New developments in psychometric and utility methods for patient-reported outcomes measurement in health economic evaluations
- FDAMA 114 and the 21st Century Cures Act: insights from payers and manufacturers, and implications for the exchange of health care economic information
- Cost-effectiveness models for innovative oncology treatments: how different methodological approaches can be used to estimate the value of novel therapies
We admit, by end of the conference we were all a little tired, but that paled to the vast education we came away with. Besides, it was great to see some familiar faces and get acquainted with our east coast colleagues.